PMID- 19097668
OWN - NLM
STAT- MEDLINE
DCOM- 20090402
LR  - 20220317
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 83
IP  - 2
DP  - 2009 Feb
TI  - Clinical significance and different levels of urinary monocyte chemoattractant 
      protein-1 in type 2 diabetes mellitus.
PG  - 215-9
LID - 10.1016/j.diabres.2008.09.048 [doi]
AB  - OBJECTIVE: Monocyte chemoattractant protein-1(MCP-1) is a cytokine that exhibits 
      most potent chemotactic activity toward monocytes. It is suggested to be 
      implicated in the development and progression of diabetic nephropathy by playing 
      a role in infiltration of monocyte/macrophage. Recent studies have demonstrated 
      that urinary monocyte chemoattractant protein-1 (uMCP-1) is different at 
      different stages of diabetic nephropathy. Based on these findings, the aim of 
      this study is to examine the level of uMCP-1 and its clinical significance at 
      different stages of diabetic nephropathy and at the same time to describe the 
      relationship between uMCP-1 and the various parameters. METHODS: Fifty-nine cases 
      with type 2 diabetes mellitus (T2DM) were divided into three groups according to 
      urine albumin excretion (UAE): normal albuminuria group, microalbuminuria group 
      and macroalbuminuria group. The levels of uMCP-1, protein excretion, blood urea 
      nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), blood 
      pressure and blood fat were measured in 59 patients with T2DM and 27 healthy 
      adults as controls. Results Compared with normal control, levels of uMCP-1 in 
      T2DM were significantly high, which were already elevated in normal albuminuria 
      group. Compared with normal albuminuria group, levels of uMCP-1 in 
      microalbuminuria group and macroalbuminuria group were significantly high. Levels 
      of uMCP-1 in macroalbuminuria group were higher than those in microalbuminuria 
      group. The level of uMCP-1 was positively correlated with UAE, systolic blood 
      pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low 
      density lipoprotein cholesterol (LDL-C) in T2DM patients, while it had no 
      significant correlation with HbA1c(,) triglyceride (TG) and high density 
      lipoprotein cholesterol (HDL-C). CONCLUSIONS: MCP-1 is suggested to be implicated 
      in the development and progression of diabetic nephropathy. It is very important 
      to measure the level of uMCP-1 in the diagnosis and intervention of early 
      diabetic nephropathy.
FAU - Wang, Qiu-yue
AU  - Wang QY
AD  - Department of Endocrinology, The First Affiliated Hospital of China Medical 
      University, Shenyang 110001, China. WQYabcd@Yahoo.com.cn
FAU - Chen, Fen-qin
AU  - Chen FQ
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081220
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albuminuria/diagnosis/etiology
MH  - Case-Control Studies
MH  - Chemokine CCL2/analysis/metabolism/*urine
MH  - Diabetes Mellitus, Type 2/complications/metabolism/*urine
MH  - Diabetic Nephropathies/*diagnosis/metabolism/urine
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
EDAT- 2008/12/23 09:00
MHDA- 2009/04/03 09:00
CRDT- 2008/12/23 09:00
PHST- 2008/06/20 00:00 [received]
PHST- 2008/09/18 00:00 [revised]
PHST- 2008/09/30 00:00 [accepted]
PHST- 2008/12/23 09:00 [entrez]
PHST- 2008/12/23 09:00 [pubmed]
PHST- 2009/04/03 09:00 [medline]
AID - S0168-8227(08)00495-6 [pii]
AID - 10.1016/j.diabres.2008.09.048 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2009 Feb;83(2):215-9. doi: 
      10.1016/j.diabres.2008.09.048. Epub 2008 Dec 20.